Mylan's Generic Advair FDA Filing Puts Added Squeeze On GSK
This article was originally published in Scrip
Executive Summary
The increasing urgency for GlaxoSmithKline PLC to build up its overall respiratory portfolio was underscored when Mylan NV confirmed it has submitted an abbreviated new drug application (ANDA) to the FDA for launch of the first generic alternative to GSK's top-selling Seretide Evohaler (salmeterol xinafoate + fluticasone propionate), known in the US as Advair Diskus.
You may also be interested in...
The Rise Of The Alt-Deal
As the pharmaceutical industry works to manage big data, improve the way drugs are used and delivered, and expand services to patients, industry is working increasingly with non-traditional partners.
Cipla-NiPPharma In Respiratory Device Deal?
Cipla Ltd. is speculated to have struck a deal with Japan's NiPPharma Co., Ltd for a device apparently meant for the Indian firm's generic Advair dry powder inhaler (DPI) but some analysts suggest that limited visibility around the trials of the firm's salmeterol + fluticasone combination in the US stay a concern for now.
Glenmark Ups Respiratory Play But Is The Digihaler Disruptive?
Glenmark Pharmaceuticals Ltd., which is building its global respiratory play, appears to be betting big on its new next-generation digital inhaler that the India firm underscores is meaningful innovation that patients can afford. The jury, though, appears to be still out on whether India’s first digital dose inhaler (DDI) can help move the adherence needle.